Prostate Cancer Early Detection
Search for other papers by Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute in
Current site
Google Scholar
PubMed
Prostate cancer is the most commonly diagnosed cancer in American men and the third leading cause of cancer-related deaths. However, the decision whether to pursue early detection of prostate cancer is complex; because not all men with prostate cancer will die of this disease, treatment is not necessary for some. These guidelines are intended to help men and clinicians choose a program for early detection of prostate cancer and make decisions about the need for prostate biopsy.
For the most recent version of the guidelines, please visit NCCN.org
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) is a national and international leader in cancer prevention, detection and treatment. Through partnership with the NCCN and a broad and growing array of scientists and research institutions worldwide, OSUCCC-James physicians and scientists focus on basic, clinical and applied research to improve patients' lives and lessen the burden of cancer around the globe.
The Ohio State University Comprehensive Cancer Center (OSUCCC) is one of only 39 NCI-designated Comprehensive Cancer Centers in the country, a status it has maintained for more than 30 years. It has seven interdisciplinary cancer research programs comprising more than 265 researchers in 14 different colleges at the University. Annual direct and indirect grant funding totals more than $120 million, including more than $51 million from the National Cancer Institute.
The James Cancer Hospital and Solove Research Institute (The James) is the adult patient care component of Ohio State's Comprehensive Cancer Center and one of only 10 freestanding cancer hospitals in the nation. Since opening in 1990, The James has successfully treated thousands of cancer patients from all 50 states and nearly 20 countries from around the world. In addition, The James has consistently been ranked as one of America's Best Hospitals for cancer care by U.S. News & World Report since 1999.
Pictured on the cover are (from top): Michael Caligiuri, MD, director of the Ohio State University Comprehensive Cancer Center and internationally renowned expert in immunity and hematologic malignancies; David Schuller, MD, CEO of The James Cancer Hospital and Solove Research Institute and internationally renowned expert in head and neck cancers; and Dennis Smith, executive director of The James Cancer Hospital and Solove Research Institute and chair of the Alliance of Dedicated Cancer Centers.
© 2019-2024 National Comprehensive Cancer Network